)
The Octapharma Annual Report offers a detailed insight into our company, highlighting who we are and the work we do.
In 2025, Octapharma continued to move forward in a challenging external environment, guided by a clear strategy and a strong focus on patients. Across the organisation, teams strengthened how we work today while building the foundations for the future.
€ bn
revenue
€ m
operating income
+
employees
:quality(80))
At our Heidelberg R&D site, scientists are combining automation, data, and hands-on expertise to speed up antibody discovery. Discover how VHH research, machine learning, and smart labs support the development of future therapies.
From donors to patients, accessibility is at the heart of Octapharma’s strategy, helping ensure reliable supply and broader access to plasma-based and recombinant therapies worldwide.
:quality(80))
At Octapharma, efficiency is about more than speed or cost. Through Octapharma Production System (OPS) 2.0, teams across our production sites are rethinking everyday processes. By turning small improvements into measurable impact, we are strengthening how we deliver medicines responsibly and sustainably.
)
In 2025, we took an important step forward by strengthening our long-term climate ambitions. Setting science-based climate targets is part of how we live our values and act responsibly for the future.
%
reduction in absolute greenhouse gas emissions by 2035
%
reduction in absolute greenhouse gas emissions by 2050
%
renewable and clean energy consumption across all operations
